Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 547

    1.

    CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.

    Esteva FJ, Wang J, Lin F, Mejia JA, Yan K, Altundag K, Valero V, Buzdar AU, Hortobagyi GN, Symmans WF, Pusztai L.

    Breast Cancer Res. 2007;9(6):R87.

    PMID:
    18086299
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.

    Yasojima H, Shimomura A, Naoi Y, Kishi K, Baba Y, Shimazu K, Nakayama T, Kim SJ, Tamaki Y, Noguchi S.

    Eur J Cancer. 2011 Aug;47(12):1779-88. Epub 2011 Jul 7.

    PMID:
    21741827
    [PubMed - indexed for MEDLINE]
    3.

    HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.

    Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L.

    Breast Cancer Res Treat. 2008 Mar;108(2):183-90. Epub 2007 Apr 28.

    PMID:
    17468948
    [PubMed - indexed for MEDLINE]
    4.

    Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support.

    Quintela-Fandino M, López JM, Hitt R, Gamarra S, Jimeno A, Ayala R, Hornedo J, Guzman C, Gilsanz F, Cortés-Funes H.

    J Clin Oncol. 2006 Aug 1;24(22):3611-8.

    PMID:
    16877728
    [PubMed - indexed for MEDLINE]
    5.

    Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

    Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM; GEICAM 9906 Study Investigators.

    J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. Epub 2008 May 27.

    PMID:
    18505968
    [PubMed - indexed for MEDLINE]
    Free Article
    6.

    Evaluation of biological pathways involved in chemotherapy response in breast cancer.

    Tordai A, Wang J, Andre F, Liedtke C, Yan K, Sotiriou C, Hortobagyi GN, Symmans WF, Pusztai L.

    Breast Cancer Res. 2008;10(2):R37. Epub 2008 Apr 29.

    PMID:
    18445275
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    7.

    High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.

    Chen SC, Chang HK, Lin YC, Hsueh S, Cheung YC, Leung WM, Tsai CS, Lo YF, Tsai HP, Shen SC, Chen MF.

    Jpn J Clin Oncol. 2008 Feb;38(2):99-105. Epub 2008 Feb 12.

    PMID:
    18270380
    [PubMed - indexed for MEDLINE]
    Free Article
    8.

    Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.

    Naoi Y, Kishi K, Tanei T, Tsunashima R, Tominaga N, Baba Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S.

    Cancer. 2011 Aug 15;117(16):3682-90. doi: 10.1002/cncr.25953. Epub 2011 Feb 8.

    PMID:
    21305539
    [PubMed - indexed for MEDLINE]
    9.

    Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

    Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S.

    J Clin Oncol. 2011 Sep 1;29(25):3351-7. Epub 2011 Jul 25.

    PMID:
    21788566
    [PubMed - indexed for MEDLINE]
    10.

    Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.

    Peintinger F, Buzdar AU, Kuerer HM, Mejia JA, Hatzis C, Gonzalez-Angulo AM, Pusztai L, Esteva FJ, Dawood SS, Green MC, Hortobagyi GN, Symmans WF.

    Ann Oncol. 2008 Dec;19(12):2020-5. Epub 2008 Jul 29.

    PMID:
    18667396
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    11.

    Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.

    Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN.

    J Clin Oncol. 2005 Jun 1;23(16):3676-85. Epub 2005 Feb 28.

    PMID:
    15738535
    [PubMed - indexed for MEDLINE]
    12.

    Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.

    Iwata H, Sato N, Masuda N, Nakamura S, Yamamoto N, Kuroi K, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Toi M.

    Jpn J Clin Oncol. 2011 Jul;41(7):867-75.

    PMID:
    21719750
    [PubMed - indexed for MEDLINE]
    Free Article
    13.

    Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.

    Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN.

    Clin Cancer Res. 2007 Jan 1;13(1):228-33.

    PMID:
    17200359
    [PubMed - indexed for MEDLINE]
    Free Article
    14.

    Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience.

    Dawood S, Gonzalez-Angulo AM, Peintinger F, Broglio K, Symmans WF, Kau SW, Islam R, Hortobagyi GN, Buzdar AU.

    Cancer. 2007 Sep 15;110(6):1195-200.

    PMID:
    17647266
    [PubMed - indexed for MEDLINE]
    Free Article
    15.

    Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

    Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gómez HL, Hortobagyi GN, Pusztai L.

    J Clin Oncol. 2006 Sep 10;24(26):4236-44. Epub 2006 Aug 8.

    PMID:
    16896004
    [PubMed - indexed for MEDLINE]
    16.

    Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.

    Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M.

    Cancer. 2007 Feb 1;109(3):496-501.

    PMID:
    17149760
    [PubMed - indexed for MEDLINE]
    Free Article
    17.

    Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.

    Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, von Minckwitz G.

    J Clin Oncol. 2010 Apr 20;28(12):2024-31. Epub 2010 Mar 22.

    PMID:
    20308670
    [PubMed - indexed for MEDLINE]
    18.

    Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival.

    Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, Yamazaki K, Hisamatsu K, Sato Y, Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Takatsuka Y; Japan Breast Cancer Research Group (JBCRG).

    Breast Cancer Res Treat. 2008 Aug;110(3):531-9. Epub 2007 Sep 19.

    PMID:
    17879158
    [PubMed - indexed for MEDLINE]
    19.

    Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.

    Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M, Ahr A.

    Zentralbl Gynakol. 2006 Apr;128(2):76-81.

    PMID:
    16673249
    [PubMed - indexed for MEDLINE]
    20.

    Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast cancer patients.

    Sánchez-Muñoz A, Dueñas-García R, Jaén-Morago A, Carrasco E, Chacón I, García-Tapiador AM, Ortega-Granados AL, Martínez-Ortega E, Ribelles N, Fernández-Navarro M, de la Torre-Cabrera C, Dueñas B, Rueda AI, Martínez J, Tortosa CR, Martín-Salvago MD, Sánchez-Rovira P.

    Am J Clin Oncol. 2010 Oct;33(5):432-7.

    PMID:
    19952716
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk